(Total Views: 794)
Posted On: 11/01/2020 5:51:41 PM
Post# of 155138
David,
We all make our own investment decisions. Despite NP discussion of share price, our individual anxieties are immaterial to company decisions.
Cytodyn, despite leronlimab, is a nobody in the pharmaceutical world. Leronlimab needs to be proven unequivocally. Following DSMB recommendations will provide that proof. I assume there will be updates on enrollment totals, but until we get to 293, they will be a bit academic.
I, despite being deeply in the red, am vehemently opposed to any actions supporting short share price at the expense of long term prospects.
I imagine Cytodyn has the same perspective or the data would already have been unblinded.
Patience required by all. A mentor of mine always reminded that “When in a hurry, dress slowly”. Methodical will get us there.
We all make our own investment decisions. Despite NP discussion of share price, our individual anxieties are immaterial to company decisions.
Cytodyn, despite leronlimab, is a nobody in the pharmaceutical world. Leronlimab needs to be proven unequivocally. Following DSMB recommendations will provide that proof. I assume there will be updates on enrollment totals, but until we get to 293, they will be a bit academic.
I, despite being deeply in the red, am vehemently opposed to any actions supporting short share price at the expense of long term prospects.
I imagine Cytodyn has the same perspective or the data would already have been unblinded.
Patience required by all. A mentor of mine always reminded that “When in a hurry, dress slowly”. Methodical will get us there.
(6)
(0)
